Ignite Creation Date:
2025-12-24 @ 7:03 PM
Ignite Modification Date:
2026-02-18 @ 12:49 PM
Study NCT ID:
NCT03310957
Status:
COMPLETED
Last Update Posted:
2025-12-12
First Post:
2017-10-11
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer
Sponsor:
Seagen Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-02-27
Start Date Type:
ACTUAL
Primary Completion Date:
2024-09-30
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-09-30
Completion Date Type:
ACTUAL
First Submit Date:
2017-10-11
First Submit QC Date:
None
Study First Post Date:
2017-10-16
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2025-09-23
Results First Submit QC Date:
None
Results First Post Date:
2025-12-12
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-01
Last Update Post Date:
2025-12-12
Last Update Post Date Type:
ESTIMATED